Bioverativ (BIVV) Announces Earnings Results
Bioverativ (NASDAQ:BIVV) posted its quarterly earnings data on Tuesday. The biotechnology company reported $1.30 EPS for the quarter, topping analysts’ consensus estimates of $0.57 by $0.73, Bloomberg Earnings reports. Bioverativ had a return on equity of 69.03% and a net margin of 40.44%.
Bioverativ (NASDAQ:BIVV) traded up $0.10 during midday trading on Tuesday, reaching $103.70. The company had a trading volume of 2,594,494 shares, compared to its average volume of 3,296,336. The company has a market capitalization of $11,230.00 and a P/E ratio of 25.37. Bioverativ has a fifty-two week low of $43.52 and a fifty-two week high of $104.30.
A number of equities analysts have commented on BIVV shares. Jefferies Group boosted their price objective on Bioverativ to $79.00 and gave the stock a “buy” rating in a research note on Thursday, January 18th. Zacks Investment Research raised Bioverativ from a “hold” rating to a “buy” rating and set a $62.00 price objective on the stock in a research note on Monday, January 8th. Morgan Stanley upgraded Bioverativ from an “underweight” rating to an “equal weight” rating in a research report on Tuesday, January 23rd. Deutsche Bank set a $53.00 target price on Bioverativ and gave the stock a “hold” rating in a research report on Monday, November 20th. Finally, Raymond James Financial downgraded Bioverativ from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 23rd. Thirteen investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $63.15.
Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.
Receive News & Ratings for Bioverativ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioverativ and related companies with MarketBeat.com's FREE daily email newsletter.